Search Results
Digital Diagnostics and Baxter Announce New Partnership to Advance Diabetic Retinopathy Detection
Digital Diagnostics and Baxter International Inc. announced a long-term strategic partnership to help front line care providers deliver high-quality care and improve care outcomes. The partnership includes plans to offer Digital Diagnostics’ industry-leading IDx-DR® autonomous AI software as a diagnostic service combined with the Welch Allyn® RetinaVue® 700 Imager.
Five Benefits of Device Connectivity
Connecting medical devices, such as infusion pumps, patient monitoring systems and dialysis machines, to the electronic medical record (EMR) can help maximize resources while providing a pathway to critical clinical information. This article is the first of an ongoing series that looks at how medical devices and technology are coming together to help advance patient care.
Baxter Presents Data Indicating Sharesource Increases Patients’ Time on Home Dialysis by More Than Three Months
Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, announced today new data indicating the use of Baxter’s Sharesource remote patient management platform with an automated peritoneal dialysis (APD) cycler may improve the clinical effectiveness of home kidney patients care by extending their time on therapy by 3.4 months.
Baxter to Present at Barclays Global Healthcare Conference
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Barclays Global Healthcare Conference on Thursday, March 17, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:00 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through September 13, 2022. About Baxter
Baxter Expands Cybersecurity Commitment, Joins Forces with U.S. Cybersecurity and Infrastructure Security Agency (CISA) Led Program
Baxter International Inc. (NYSE:BAX), a leading global medtech leader, announced that it has received authorization from the Common Vulnerability and Exposures (CVE®) program to be a CVE Numbering Authority. As a CVE Numbering Authority (CNA), Baxter is responsible for the assignment of CVE identifiers to cyber vulnerabilities for Baxter and Hillrom commercially available products, and for publicly disclosing information about the vulnerabilities in the associated CVE Record.
Providing Regulatory Guidance at BPS
Our Regulatory Affairs team at Baxter BioPharma Solutions navigates a diverse product portfolio and evolving challenges to bring new products to market, support contract manufacturing clients and advance our mission.
Baxter to Present at the Raymond James 43rd Annual Institutional Investors Conference
Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Raymond James 43rd Annual Institutional Investors Conference on Monday, March 7, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 8:40 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through March 6, 2023.
Baxter Issues Urgent Safety Communication to Reinforce Important Safety Information Regarding Upstream Occlusion Alarms for all Spectrum V8 and Spectrum IQ Infusion Pumps
Baxter International Inc. announced today it has issued an Urgent Safety Communication to reinforce important safety information regarding upstream occlusion alarms for all Spectrum V8 and Spectrum IQ infusion pumps. Incorrect administration set setup and/or incomplete resolution of upstream occlusion alarms may result in reduced delivery or non-delivery of medication, in some cases without alerting the user via pump alarm.
Baxter Reports Fourth-Quarter and Full-Year 2021 Results
Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter and full year ended Dec. 31, 2021, and provided its financial guidance for full-year and first-quarter 2022. Fourth-quarter and full-year 2021 results reflect 19 days of contribution from Hillrom Holdings, Inc. (Hillrom) subsequent to Baxter’s acquisition of the company on Dec. 13, 2021.
Baxter Declares Quarterly Dividend
Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced that its Board of Directors has declared a quarterly cash dividend of $0.28 per share of common stock. The dividend is payable on April 1, 2022, to shareholders of record as of Feb. 25, 2022. The indicated annual dividend rate is $1.12 per share of common stock. About Baxter